We are thrilled to announce that PipeBio is joining forces with Benchling, a company that shares our passion for accelerating scientific discovery through modern, intuitive software. By combining our expertise in bioinformatics with Benchling’s leading cloud platform, we’re poised to help shape the future of biologics discovery.
Since day one, PipeBio’s mission has been to make biologics discovery easier and faster for scientists. Our cloud-native product helps researchers screen and analyze millions of sequences and identify key candidates. As biologics play an increasingly central role in R&D pipelines, the demand for adaptable, powerful tools is growing. By joining Benchling, we can offer the most complete end-to-end solution for biologics discovery and development, from screening millions of sequences for hits to developing the processes to manufacture clinical candidates.
PipeBio will continue to operate as usual, but now with the added resources and capabilities of Benchling. We continue to be committed to continuously expanding the capabilities of PipeBio to support innovative science.
Through Benchling’s developer program, we have already built an integration between PipeBio and Benchling, and the response from our shared customers has been enthusiastic. Over time, we will extend this integration to further streamline the discovery process. A truly open platform is one of the core pillars of Benchling’s strategy, so we’ll continue to support integration with other products as well.
As we look ahead, it’s clear that the landscape of biologics research is evolving rapidly. Scientists are pairing large-scale experimental data with cutting-edge AI-driven approaches to design more effective therapeutics faster than ever before. The shift happening in biologics from traditional drug discovery to computationally-guided drug design is opening new possibilities. In partnership with Benchling, PipeBio will play a key role in the future of biologics research in three important ways:
- Sequence intelligence: PipeBio’s deep capabilities in sequence analysis will become central to the design and registration of complex large molecules.
- Screening and hit selection: Our analysis and visualization tools will help scientists connect sequence, structure, and functional data, allowing for better-informed candidate selection.
- AI-enabled discovery: With both out-of-the-box AI models and integration capabilities for customer models, PipeBio will help scientists use predictions throughout the discovery and engineering process, simplifying the collaboration between wet and dry labs.
We're excited about joining Benchling and expanding our shared vision to build the next generation of solutions for biologics R&D.
Thank you to our customers and partners for your support. Stay tuned — there's much more ahead!
